MedTrace Logo

A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine Fibroids

NCT02580578 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2020-02-28

No results posted yet for this study

Summary

This study will characterize the treatments and outcomes associated with different uterine fibroid treatments in Canada, to understand patients' preferences and satisfaction with different medical and procedural interventions. The study will also assess the effectiveness of ulipristal acetate (Fibristal®) in controlling bleeding, reducing fibroid volume and symptoms, and improvement in patient's quality of life.

Conditions

  • Leiomyoma

Interventions

OTHER

No Intervention

No intervention is administered in this study.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Carmen Enciu · Allergan

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02580578 on ClinicalTrials.gov